Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment : Relationship Between Antibodies and Severity of Thyroid Dysfunction
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
OBJECTIVE: The purpose of this study was to identify predictive and risk factors for the development of immune-related endocrinopathies and to analyze the incidence and characteristics of immune-related endocrinopathies in our population Design: A retrospective, single-centre cohort carried out at Gregorio Marañón Hospital between January 2018 -December 2019.
METHODS: A total of 163 patients were enrolled. In January 2018 and December 2019, we treated patients who underwent ICI treatment in the Medical Oncology Department of General University Hospital Gregorio Marañón, a tertiary care public hospital in Madrid, as part of an observational, retrospective, single-center cohort study.
RESULTS: Endocrinopathies were diagnosed in 19.5% of the patients (n=32). The tumours with the highest incidence of endocrinopathies were non-small cell lung cancer (25,9%), kidney cell cancer (25%) and hepatocarcinoma (20%). Among the 32 patients who developed endocrinopathy, 18,8%, 19,13%, and 21,28% received anti-CTLA-4, anti-PD-1 and anti-PDL-1, respectively. Thyroid dysfunction was the most frequent endocrinopathy (12,8%). A higher percentage of patients with negative antiTPO and antiTG antibodies developed G1 hypothyroidism compared to patients with positive antibodies who developed a higher proportion of G2 hypothyroidism. The presence of an initial phase of thyrotoxicity was not related to greater severity. We observed longer progression-free survival in patients who developed thyroid dysfunction.
CONCLUSION: Pre-existing antibodies were independently associated with endocrinopathies. Moreover, our study let us conclude that the presence of thyroid autoantibodies may be related to its severity. It is important to determine anti-thyroid antibodies prior to the start of immunotherapy as a risk factor for thyroid dysfunction, which in turn is a prognostic marker.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders drug targets - (2024) vom: 14. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miguélez González, María [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Endocrinopathies |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0118715303280679240206100137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368527581 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368527581 | ||
| 003 | DE-627 | ||
| 005 | 20240216232956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118715303280679240206100137 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1296.xml |
| 035 | |a (DE-627)NLM368527581 | ||
| 035 | |a (NLM)38362680 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miguélez González, María |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment |b Relationship Between Antibodies and Severity of Thyroid Dysfunction |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a OBJECTIVE: The purpose of this study was to identify predictive and risk factors for the development of immune-related endocrinopathies and to analyze the incidence and characteristics of immune-related endocrinopathies in our population Design: A retrospective, single-centre cohort carried out at Gregorio Marañón Hospital between January 2018 -December 2019 | ||
| 520 | |a METHODS: A total of 163 patients were enrolled. In January 2018 and December 2019, we treated patients who underwent ICI treatment in the Medical Oncology Department of General University Hospital Gregorio Marañón, a tertiary care public hospital in Madrid, as part of an observational, retrospective, single-center cohort study | ||
| 520 | |a RESULTS: Endocrinopathies were diagnosed in 19.5% of the patients (n=32). The tumours with the highest incidence of endocrinopathies were non-small cell lung cancer (25,9%), kidney cell cancer (25%) and hepatocarcinoma (20%). Among the 32 patients who developed endocrinopathy, 18,8%, 19,13%, and 21,28% received anti-CTLA-4, anti-PD-1 and anti-PDL-1, respectively. Thyroid dysfunction was the most frequent endocrinopathy (12,8%). A higher percentage of patients with negative antiTPO and antiTG antibodies developed G1 hypothyroidism compared to patients with positive antibodies who developed a higher proportion of G2 hypothyroidism. The presence of an initial phase of thyrotoxicity was not related to greater severity. We observed longer progression-free survival in patients who developed thyroid dysfunction | ||
| 520 | |a CONCLUSION: Pre-existing antibodies were independently associated with endocrinopathies. Moreover, our study let us conclude that the presence of thyroid autoantibodies may be related to its severity. It is important to determine anti-thyroid antibodies prior to the start of immunotherapy as a risk factor for thyroid dysfunction, which in turn is a prognostic marker | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ICI | |
| 650 | 4 | |a PFS. | |
| 650 | 4 | |a endocrinopathies | |
| 650 | 4 | |a severity | |
| 650 | 4 | |a thyroid antibodies | |
| 700 | 1 | |a Galdón Sanz-Pastor, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Áñez Gómez, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Brox Torrecilla, Noemi |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz Moreno, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a González Fernández, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Maricel Rivas, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a López Guerra, Aurelio |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Arranz, José Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Márquez Rodas, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Escudero, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Sanjurjo, María |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Vallejo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a González Albarrán, Olga |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders drug targets |d 2006 |g (2024) vom: 14. Feb. |w (DE-627)NLM161976174 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:14 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715303280679240206100137 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 14 |c 02 | ||